Nasdaq · Healthcare
Akebia Therapeutics, Inc. (AKBA)
As-reported financials and recent SEC filings for Akebia Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$236.2M
Net income
$-5.3M
Net margin
-2.3%
Diluted EPS
$-0.02
ROE
-16.4%
P/E (TTM)
—
Market cap
$305.8M
Debt / equity
1.5×
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $236.2M | $160.2M | $194.6M | $292.5M | $211.7M |
| Gross profit | $196.7M | $97.0M | $120.5M | $206.9M | $61.0M |
| Operating income | $23.5M | $-50.5M | $-46.3M | $-80.8M | $-264.5M |
| Net income | $-5.3M | $-69.4M | $-51.9M | $-94.2M | $-282.0M |
| Diluted EPS | $-0.02 | $-0.33 | $-0.28 | $-0.52 | $-1.70 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →8-K2026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →42026-06-22
View on EDGAR →SCHEDULE 13G2026-05-12
View on EDGAR →Go deeper on AKBA
Search Akebia Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.